Introduction and Overview
On November 4, 2026, the Centers for Medicare & Medicaid Services (CMS) issued a final rule with comment period for the Calendar Year (CY) 2027 Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) payment system (CMS-1850-FC) (the "Final Rule"). The Final Rule updates OPPS and ASC payment rates by 2.3 percent for providers meeting quality reporting requirements, reflecting a 3.2 percent market basket increase reduced by a 0.9-percentage-point productivity adjustment. This alert focuses on four noteworthy areas: Software as a Medical Service (SaMS), the 340B Program, Emergency Medical Treatment and Active Labor Act (EMTALA), and the Inpatient Only (IPO) list. The Final Rule becomes effective January 1, 2027, but comments will be accepted until January 4, 2027.
Provider-Based Attestations: The Final Rule also implements Section 6225 of the Consolidated Appropriations Act, 2026, which, beginning January 1, 2028, conditions OPPS payment for off-campus outpatient departments on billing under a separate National Provider Identifier (NPI) and submitting initial and recurring provider-based attestations. Because these changes have substantial compliance implications, they will be the subject of a standalone, forthcoming alert.
I. Software as a Medical Service (SaMS)
Key Takeaways: CMS is changing its terminology from "Software as a Service" (SaaS) to "Software as a Medical Service" (SaMS), creating a new status indicator "O1" for SaMS payable under the OPPS, and assigning all such services to New Technology Ambulatory Payment Classifications (APCs) as an interim step toward a broader payment policy. CY 2027 payment rates for these services are held consistent with CY 2026 OPPS rates, and SaMS will be paid without multiple procedure discounting. CMS is also moving 14 "SaMS analyses performed on laboratory tests" (stand-alone algorithmic analyses of data from a prior lab test) from the Clinical Laboratory Fee Schedule to New Technology APCs under the OPPS and will assign any new such codes to New Technology APCs going forward.
Next Steps for Providers: Hospitals and software developers should review Addendum B to the Final Rule to confirm the status indicator and APC assignment for each SaMS code they bill, and update chargemasters and billing systems for the "O1" indicator and the transition of affected algorithmic analyses from the Clinical Laboratory Fee Schedule (CLFS). Because CMS describes these policies as interim and expects to consider further proposals for CY 2028, interested stakeholders should prepare to engage in the next rulemaking cycle.
II. 340B Drug Pricing Program
Key Takeaways: Relying on its CY 2026 drug acquisition cost survey, CMS will pay for 340B-acquired drugs at Average Sales Price (ASP) minus 28 percent in CY 2027, which CMS estimates will reduce Original Medicare drug payments by $4.35 billion in the first year. Because the policy must be budget neutral, payments for non-drug services will increase by an equivalent amount. Separately, CMS is increasing the remedy offset reduction from the previous $7.8 billion lump-sum payment to the OPPS conversion factor for non-drug items and services from 0.5 percent to 2 percent (CMS had proposed 3 percent), excluding hospitals that enrolled in Medicare after January 1, 2018. CMS estimates the $7.8 billion offset will be fully recovered in CY 2031.
Next Steps for Providers:. 340B hospitals should model the combined revenue impact of the ASP minus 28 percent rate and the 2 percent offset on their CY 2027 budgets, update billing practices for the modifier requirements ("JG" for 340B drugs subject to the reduction, "TB" for exempt 340B drugs, and the new "ND" modifier for all separately payable non-340B drugs), review their Medicare Advantage contracts to see how this change will impact payments under those agreements, and follow any potential legal challenges to the reduced payment rate in light of prior 340B litigation.
III. EMTALA
Key Takeaways: CMS is allowing hospital accrediting organizations (AOs) with Medicare deeming authority to assess compliance with EMTALA administrative requirements under 42 C.F.R. § 489.20 (including required signage, the central emergency department log, five-year retention of transfer records, and the on-call physician list) during routine accreditation and reaccreditation surveys. CMS is amending 42 C.F.R. § 488.5(a) to require AOs to document their EMTALA inspection procedures. Enforcement of the substantive patient care protections at 42 C.F.R. § 489.24, including complaint investigations, remains exclusively with CMS and the Office of Inspector General (OIG).
Next Steps for Providers: Hospitals, including Critical Access Hospitals and Rural Emergency Hospitals, should audit their EMTALA signage, central log, transfer records, and on-call lists now and incorporate these items into accreditation survey readiness, since deficiencies may surface in routine surveys rather than only in complaint investigations.
IV. Continued Phaseout of the IPO List
Key Takeaways: In the second year of its three-year phase-out of the IPO list, CMS is removing 637 services across numerous clinical families, including auditory, digestive, endocrine, female genital, hemic and lymphatic, integumentary, male genital, maternity care and delivery, mediastinum and diaphragm, respiratory, and urinary. These services may now be paid by Medicare in the hospital outpatient setting when clinically appropriate, giving physicians greater flexibility to choose the site of service. CMS also added 618 of the removed procedures to the ASC Covered Procedures List.
Next Steps for Providers: Hospitals should identify which of the removed procedures they perform, update utilization review and patient status protocols, and establish clinical circumstances supporting inpatient admission for affected procedures. Removal from the IPO list does not mean that CMS has determined that a procedure is never medically appropriate as an inpatient procedure. Rather, the procedure is no longer categorically required to be inpatient under Medicare payment rules. Accordingly, hospitals will have to carefully document patient-specific factors supporting an inpatient admission when providers determine that the inpatient site of service is appropriate for these procedures. Hospitals should also plan for the final year of the phase-out, which is expected to include remaining neurologic, cardiovascular, and transplant procedures on the IPO list.
***
For further information or analysis about the Final Rule, please contact one of the authors or any other member of Baker Donelson's Reimbursement or Health Law Group.